Chris Schaber, President & CEO of Soligenix Inc (SNGX:OTC), shares of this company is focused on developing therapies for rare diseases.
Soligenix is a rare disease company that focuses in areas of unmet medical need. What makes Soligenix unique is the government funding we receive with up to $57 million in contract funding. It not only allows us to advance the biodefense business segment, but also allows us to manage our cash burn very effectively and offset some of the expensive of our biotherapeutics business segment.
In the biotherapeutics, we have late stage programs. We have a phase three clinical program for the treatment of cutaneous T-cell lymphoma. This has received both orphan drug and fast track designation from the FDA. We also have the phase three clinical program for the treatment of pediatric Crohn’s disease also orphaned and fast tracked.
Our vaccine biodefense, it’s funded entirely by the government. The nice thing here is that we have very good technology. We have ricin toxin vaccine that shown very good data to date in a preclinical animal model. We have a therapeutic Orbishield for gastrointestinal acute radiation syndrome, also funded nicely by both BARDA and the NIH and have shown some very nice data today
The problem with any area like rare diseases is finding companies that will develop and have the therapies to develop in these areas. We look for a combination of safe and effective therapies, but therapies that are also well understood and characterized before going into late stage development.